Table 5.
Most common adverse events (any grade)
| Any Grade, n (%) | Apatinib Based N = 56 |
Chemotherapy Based N = 107 |
P | Apatinib plus Chemotherapy N = 34 |
Chemotherapy Alone N = 97 |
P | |
|---|---|---|---|---|---|---|---|
| Hematological events | |||||||
| Neutropenia | 45 (80.4) | 88 (82.2) | 0.77 | 26 (76.5) | 79 (81.4) | 0.53 | |
| Anemia | 18 (32.1) | 57 (53.3) | 0.01 | 8 (23.5) | 53 (54.6) | 0.002 | |
| Thrombocytopenia | 10 (17.9) | 17 (15.9) | 0.75 | 7 (20.6) | 17 (17.5) | 0.69 | |
| Non-hematological events | |||||||
| Peripheral neuropathy | 15 (26.8) | 51 (47.7) | 0.01 | 8 (23.5) | 45 (46.4) | 0.02 | |
| Nausea/vomiting | 8 (14.3) | 39 (36.4) | 0.003 | 4 (11.8) | 38 (39.2) | 0.006 | |
| Diarrhea | 2 (3.6) | 16 (15.0) | 0.05 | 0 | 16 (16.5) | 0.01 | |
| AST/ALT alterations | 19 (33.9) | 36 (33.6) | 0.97 | 9 (26.5) | 32 (33.0) | 0.48 | |
| Fatigue | 27 (48.2) | 46 (43.0) | 0.52 | 12 (35.3) | 39 (40.2) | 0.61 | |
| Proteinuria | 13 (23.2) | 3 (2.8) | < 0.001 | 9 (26.5) | 3 (3.1) | < 0.001 | |
| Hypertension | 33 (58.9) | 2 (1.9) | < 0.001 | 21 (61.8) | 1 (1.0) | < 0.001 | |
| Hand-foot Syndrome | 22 (39.3) | 8 (7.5) | < 0.001 | 12 (35.3) | 8 (8.2) | < 0.001 | |
| Alopecia | 29 (51.8) | 78 (72.9) | 0.007 | 17 (50.0) | 72 (74.2) | 0.009 |